Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎, New York, NY 10065
(646) 856-9261
[email protected]

Alan P. Venook, M.D.


Alan P. Venook, M.D. is the Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California (UCSF) San Francisco and the Shorenstein Associate Director for Program Development at the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. Venook served as the Founding Chair of the National Cancer Institute’s Hepatobiliary Task Force and from 2011 to 2016 served as Chair of the GI Cancer Committee in the Alliance. A nationally recognized expert in colorectal and liver cancers, Dr. Venook served as Principal Investigator for the CALGB/SWOG 80405 trial which, amongst other findings, helped to clearly demonstrate the difference in outcome between colon cancers developing in the right vs. left side of the large intestine. Dr. Venook received his B.A. from Rutgers University and his M.D. from the UCSF School of Medicine.